Heat dissipation in Sm3+ and Zn2+ co-substituted magnetite (Zn0.1SmxFe2.9-xO4) nanoparticles coated with citric acid and pluronic F127 for hyperthermia application

In this work, Sm3+ and Zn2+ co-substituted magnetite Zn0.1SmxFe2.9-xO4 (x = 0.0, 0.01, 0.02, 0.03, 0.04 and 0.05) nanoparticles, have been prepared via co-precipitation method and were electrostatically and sterically stabilized by citric acid and pluronic F127 coatings. The coated nanoparticles were well dispersed in an aqueous solution (pH 5.5). Magnetic and structural properties of the nanoparticles and their ferrofluids were studied by different methods. XRD studies illustrated that all as-prepared nanoparticles have a single phase spinel structure, with lattice constants affected by samarium cations substitution. The temperature dependence of the magnetization showed that Curie temperatures of the uncoated samples monotonically increased from 430 to 480 °C as Sm3+ content increased, due to increase in A-B super-exchange interactions. Room temperature magnetic measurements exhibited a decrease in saturation magnetization of the uncoated samples from 98.8 to 71.9 emu/g as the Sm3+ content increased, which is attributed to substitution of Sm3+ (1.5 µB) ions for Fe3+ (5 µB) ones in B sublattices. FTIR spectra confirmed that Sm3+ substituted Zn0.1SmxFe2.9-xO4 nanoparticles were coated with both citric acid and pluronic F127 properly. The mean particle size of the coated nanoparticles was 40 nm. Calorimetric measurements showed that the maximum SLP and ILP values obtained for Sm3+ substituted nanoparticles were 259 W/g and 3.49 nHm2/kg (1.08 mg/ml, measured at f = 290 kHz and H = 16kA/m), respectively, that are related to the sample with x = 0.01. Magnetic measurements revealed coercivity, which indicated that hysteresis loss may represent a substantial portion in heat generation. Our results show that these ferrofluids are potential candidates for magnetic hyperthermia applications

Biodegradable magnetic microspheres for drug targeting, temperature controlled drug release, and hyperthermia

Magnetic microspheres (MMS) used for magnetic drug targeting consist of magnetic nanoparticles (MNP) and a pharmaceutical agent embedded in a polymeric matrix material. The application of MNP for drug targeting enables guiding the MMS to a target area, imaging the position of the MMS with magnetic particle imaging, and finally inducing drug release. As latter takes place by degradation of the MMS or diffusion through the matrix, an increase in temperature, e.g. through magnetic hyperthermia, leads to an accelerated drug release. Here, MMS consisting of poly(lactic-coglycolic) acid (PLGA) with different monomer ratios were prepared by an oil-in-water emulsion evaporation method. The model drug Camptothecin (CPT) and magnetic multicore nanoparticles (MCNP) with a high specific heating rate were embedded into the microspheres. We obtained MMS in the preferred size range of 1 to 2 μm with a concentration of MCNP of 16wt%, a drug load of about 0.5wt% and an excellent heating performance of 161 W/gMMS. Investigations of the drug release behaviour showed an accelerated drug release when increasing the temperature from 20 °C to 37 °C or 43 °C by using a water bath. In addition, an increase in drug release of about 50% through magnetic heating of the MMS up to 44 °C compared to 37 °C was observed. By this, a magnetic hyperthermia induced CPT release from PLGA MMS is demonstrated for the very first time

3D printed measurement phantoms for evaluation of magnetic particle imaging scanner

To assess the potential and capability of different MPI scanner designs and architectures, defined reference phantoms for imaging studies are required. For the preparation of well-defined structures as well as realistic vessel structures, 3D printed molds were filled with magnetic nanoparticles embedded into a long term stable polymeric matrix or perfused with a flowing ferrofluid. Different types and layouts of 3D printed phantoms will be presented which were imaged by means of MPI successfully

Ferrimagnetic large single domain iron oxide nanoparticles for hyperthermia applications

This paper describes the preparation and obtained magnetic properties of large single domain iron oxide nanoparticles. Such ferrimagnetic particles are particularly interesting for diagnostic and therapeutic applications in medicine or (bio)technology. The particles were prepared by a modified oxidation method of non-magnetic precursors following the green rust synthesis and characterized regarding their structural and magnetic properties. For increasing preparation temperatures (5 to 85 °C), an increasing particle size in the range of 30 to 60 nm is observed. Magnetic measurements confirm a single domain ferrimagnetic behavior with a mean saturation magnetization of ca. 90 Am2/kg and a size-dependent coercivity in the range of 6 to 15 kA/m. The samples show a specific absorption rate (SAR) of up to 600 W/g, which is promising for magnetic hyperthermia application. For particle preparation temperatures above 45 °C, a non-magnetic impurity phase occurs besides the magnetic iron oxides that results in a reduced net saturation magnetization

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

The SIB Swiss Institute of Bioinformatics' resources: focus on curated databases

The SIB Swiss Institute of Bioinformatics (www.isb-sib.ch) provides world-class bioinformatics databases, software tools, services and training to the international life science community in academia and industry. These solutions allow life scientists to turn the exponentially growing amount of data into knowledge. Here, we provide an overview of SIB's resources and competence areas, with a strong focus on curated databases and SIB's most popular and widely used resources. In particular, SIB's Bioinformatics resource portal ExPASy features over 150 resources, including UniProtKB/Swiss-Prot, ENZYME, PROSITE, neXtProt, STRING, UniCarbKB, SugarBindDB, SwissRegulon, EPD, arrayMap, Bgee, SWISS-MODEL Repository, OMA, OrthoDB and other databases, which are briefly described in this article

Ferrimagnetic Large Single Domain Iron Oxide Nanoparticles for Hyperthermia Applications

This paper describes the preparation and obtained magnetic properties of large single domain iron oxide nanoparticles. Such ferrimagnetic particles are particularly interesting for diagnostic and therapeutic applications in medicine or (bio)technology. The particles were prepared by a modified oxidation method of non-magnetic precursors following the green rust synthesis and characterized regarding their structural and magnetic properties. For increasing preparation temperatures (5 to 85 °C), an increasing particle size in the range of 30 to 60 nm is observed. Magnetic measurements confirm a single domain ferrimagnetic behavior with a mean saturation magnetization of ca. 90 Am2/kg and a size-dependent coercivity in the range of 6 to 15 kA/m. The samples show a specific absorption rate (SAR) of up to 600 W/g, which is promising for magnetic hyperthermia application. For particle preparation temperatures above 45 °C, a non-magnetic impurity phase occurs besides the magnetic iron oxides that results in a reduced net saturation magnetization

Magnetic Microspheres for MPI and magnetic actuation

Magnetic particle imaging (MPI) systems do not only allow for the visualization of the distribution of magnetic nanoparticles, but the magnetic fields of an MPI scanner can be also used to apply a magnetic force or a torque. This enables the actuation of magnetic particles. Here, we demonstrate that magnetic microspheres (MMS) are well suitable candidates for the actuation and visualization with MPI. By means of magnetic particle spectrometer (MPS) measurements, a promising imaging performance of the MMS for MPI was confirmed. We show that MMS can be actuated by rotating focus fields of a preclinical MPI scanner. Since the used MMS can carry therapeutics, which can be released by means of hyperthermia, this approach paves the way towards an MPI monitored targeted drug delivery